Matthew Durdy, Chief Business Officer discusses the role and work of the Cell Therapy Catapult

1. Growing a UK Cell Therapy Industry
Delivering
Health & Wealth
Matthew Durdy, Chief Business Officer
December 2013
ct.catapult.org.uk
Catapult is a Technology Strategy Board programme

2. The Cell Therapy (and Regenerative Medicine)
Opportunity
*US Market data
•
•
•
•
•
•
http://www.cancer.org/cancer/cancerbasics/economic-impact-of-cancer
http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf
http://www.cdc.gov/heartdisease/facts.htm
http://www.pdf.org/en/parkinson_statistics
http://www.provengehcp.com/FAQs.aspx
http://www.dermagraft.com/about/efficacy/
2

3. Why a Catapult?
• Learning
• Excellence
• Leadership
• Efficiency
• Risk taking
3

4. Assets -Facilities and Teams
• Facilities
• Business Team
•
Business development
Capacity for 80-100 people
•
Health economics
•
Clinical research cluster
•
Business models
•
Global location
•
1200 sq m on 12th floor
•
• Translational Labs and Team
•
Process development
•
Analytical development
•
GMP process proving
• Clinical Trial and Regulatory
Team
•
Regulatory
•
Clinical operations
4

5. Management Team and Board
Keith Thompson
Chief Executive
(Director, Scottish
National Blood
transfusion Service,
Serologicals)
Dr John Brown, CBE,
FRSE
Chairman
BTG plc, Acambis, CAT
Dr Natalie Mount
Dr Stephen Ward
Chief Clinical Officer
(Director Pfizer,
Neusentis. Cambridge,
UCL)
Chief Operating Officer
(Director, Stabilitech,
Onyvax. Southampton,
Imperial)
Matthew Durdy
Chief Business Officer
(Director, Aqix, Biotec,
CDC. Oxford, Chicago)
Professor
Johan Hyllner
Chief Scientific Officer
(Director, Cellectis,
Cellartis, Vitrolife)
Headcount: 65
Professor Marc Turner
Non-executive Director
Edinburgh, SNBTS
Professor Michael
Whitaker
Non-executive Director
NE Stem Cell Institute
Tim Edwards
Non-executive Director
Chairman, Bio Industry
Association
Dr Zahid Latif
Non-executive Director
Technology Strategy
Board
Nick Higgins
Non-executive Director
Consort Medical,
Intercytec
22/11/2013
5

6. Catapult Themes
Risk
Catapult is a Technology Strategy Board programme

7. Management of Perceived Risk
Example
Nature
Solution
EU
Regulation
Not
Understood
Expert
Advice
Economics
Not Clear
Prepare
Data
GMP
Not done
Expert
partner
Therapy
Not proven
Share
Risk?
7

8. Catapult Themes
Funding
Catapult is a Technology Strategy Board programme

9. Commercial Development Plan
?
Start
Commercial
Development
Plan
Tasks
• Innovation
• Quality
• Data
Product
• Substance
• Process
• Regulation
• Information
Group
• Identity
• Quantity
• Diagnostic
Need
• Patient
• Clinician
• Payer
• Seller
9

10. Funding for cell therapy in the UK
Govt.
Support
Medical
Charities
Commercial
Development
Plan
Financial
Investment
Corporate
Venturing
10

11. Successful commercialization depends on both
regulatory approval and optimal market access
Quality
Safety
Efficacy
REGULATORY APPROVAL
11
Comparative Clinical & CostEffectiveness; Budget Impact
MARKET ACCESS

12. Lab - Pilot - Scale
Catapult Multi Functional development Pod
Commercial Scale
Catapult GMP Proving Lab
T
e
c
h
t
r
a
n
sf
e
r
12

13. Collaboration
1+1 = 3
Client knowledge +
Expert capabilities =
Better outcome
Up to 80% UK Technology Strategy Board
Funding available for collaboration with SME
Partner
Project
Input
Funding
Ratio
TSB Grant
SME
£1m
60%
£0.6m
Catapult
£1m
100%
£1.0m
Total
£2m
£1.6m
80%

14. Sharing the outputs and opportunities
14

15. Partners
• Cooperation on
manufacturing
platforms
• Project sourcing and
funding
• International
collaboration
15

16. Project Examples
• Share of expertise
• Support for in house projects
• New delivery device to reduce injection
pain
• Phase 2 clinical trials
• Scale up, Assays, Freezing and distribution
of cells
Large Cap
Company
• Manufacturing partner, Regulatory,
Clinical trial design and delivery
• Immunomodulation
• Regulatory, Clinical trial design, business
models
16

17. Activities
Proof of Principle
• Scientific, clinical, regulatory, commercial
Non-clinical
• Safety, toxicology, GMP proving, assays
Suitability
• Commercial
Development
Plan
Clinical
• Safety and efficacy, investible data
Platform
• Generic issues and large collaborations
17

18. Working models and finance
Nature of project Paid for by:
Carried out
by:
Ownership
of outputs
Finance
Core Project
Catapult
Catapult
Catapult
£70m/
5 years
Contracted
Development
Client
Catapult
Client
£10m/
Per year
Grant or
Catapult and
partner
Catapult
and
partner
Outputs
shared
Industry
Collaboration
£10m/
Per year
18

19. Gateway Criteria

20. Building the portfolio
hESC
Blood
Bone & Cartilage
Cardiovascular
Dermatology/Wound
Healing
Diabetes
Gastroenterology
Immunology
Liver
Metabolic
Neurological
Oncology
Ophthalmology
Respiratory
Other
iPS
MSC
Immune
Cell
Other
Somatic

21. Outputs
Life changing therapies
Investible propositions
Industry changing innovation
Skilled leaders
UK leadership

22. Summary: The Cell Therapy Catapult
Strong first year of growth
Matthew Durdy
info@ct.catapult.org.uk
Laboratories and teams up and
running, 60+
http://ct.catapult.org.uk
Twitter: @CTCatapult
Large and small collaborations
Global interaction
Industry success is our success

23. Researchers
Industry
Cell Therapy
Catapult
NHS
Catapult is a Technology Strategy Board programme
Investment